Apabetalone has great potential but poor management.

The company is currently insolvent and the IP is pledged as collateral for a 12 million loan + accrued interest. The btd needs fda approval and there is a planned Phase 3 trial which requires funding. At .05 per share, raising 50mil(usd) for trial costs woul decimate current shareholders and is too dilutive.

DMs current plan is to fund the trial with proceeds from the sale of Zen-3694 a promising therapy currently in several trials. This does make sense since Zenith Capital, a resverlogix corp spinoff holds 2 major assets - Zen-3694 and a 5-8% royalty on sales of RVX-208 which could fetch ~ 83bil in gross sales over its patent life. Zenith Cap receives no revenues until RVX-208 is approved and marketed. 

it's been a long journey stalled by Betonmace missing its trial endpoints. Fortunately, Zen appears to be a therapy nearing approval with a minimum value exceeding 1.5bil.

There you have it as I see it - if this does materialize you're looking at another 2-3 years. In the meantime it's still in a very precarious position.

Chicagoest